{"DataElement":{"publicId":"2005459","version":"4","preferredName":"CTC Adverse Event Muscle Grade","preferredDefinition":"in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of an adverse event for the supraordinate term generalized or specific muscle weakness (not due to neuropathy) - select using a graded scale.","longName":"CTC_AE_MM_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192470","version":"1","preferredName":"CTC Adverse Event Muscle","preferredDefinition":"information related to the CTC adverse event of a muscle.","longName":"CTC_AE_MM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177419","version":"1","preferredName":"Muscle","preferredDefinition":"Muscle Tissue; an animal tissue consisting predominantly of contractile cells.","longName":"Muscle","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Muscle Tissue","conceptCode":"C12435","definition":"Tissue responsible for the body movements and the shape and size changes of internal organs.  Muscle tissue is composed of specialized contractile cells.  There are two types of muscle tissue recognized: striated and smooth muscle.  The striated muscle tissue is further subdivided into skeletal, visceral striated, and cardiac muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-523D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E98F11AD-B352-14E3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017659","version":"3","preferredName":"CTC Adverse Event Muscle Grade","preferredDefinition":"in CTC category Musculoskeletal/Soft Tissue, assessment of the severity of an adverse event for the supraordinate term generalized or specific muscle weakness (not due to neuropathy) - select using a graded scale.","longName":"CTC_AE_MM_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BB98-6C34-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Life-threatening; disabling","ValueMeaning":{"publicId":"2566359","version":"1","preferredName":"Life-threatening; disabling","longName":"2566359","preferredDefinition":"Life-threatening; disabling","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D044-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BB9A-6C34-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Symptomatic and interfering with function, but not interfering with ADL","ValueMeaning":{"publicId":"2566357","version":"1","preferredName":"Symptomatic and interfering with function, but not interfering with ADL","longName":"2566357","preferredDefinition":"Symptomatic and interfering with function, but not interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D042-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BB9C-6C34-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Asymptomatic, weakness on physical exam","ValueMeaning":{"publicId":"2566356","version":"1","preferredName":"Asymptomatic, weakness on physical exam","longName":"2566356","preferredDefinition":"Asymptomatic, weakness on physical exam","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D041-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BB9E-6C34-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptomatic and interfering with ADL","ValueMeaning":{"publicId":"2566358","version":"1","preferredName":"Symptomatic and interfering with ADL","longName":"2566358","preferredDefinition":"Symptomatic and interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D043-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BBA0-6C34-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"Normal","ValueMeaning":{"publicId":"2567281","version":"1","preferredName":"Normal","longName":"2567281","preferredDefinition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C43B5203-BBA2-6C34-E034-0003BA12F5E7","beginDate":"2002-12-26","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C43B5203-BB94-6C34-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"COOPERM","dateModified":"2017-02-16","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Muscle weak","type":"Preferred Question Text","description":"CTC Adverse Event Muscle weakness generalized or specific area (not due to neuropathy) Select Grade","url":null,"context":"CTEP"},{"name":"1-COMMENT","type":"COMMENT","description":"(not due to neuropathy)","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Muscle weakness generalized or specific area Select Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C43B64C0-3E36-69D5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-11-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}